Last reviewed · How we verify
NCT03191565: mDIARY
Using Smartphones for Selfmonitoring of Skill-use i Dialectical Behavior Therapy
NA trial testing Paper diary sheet in Borderline Personality Disorder in 78 participants. Status unknown.
30 December 2019
Quick facts
| Lead sponsor | Region of Southern Denmark |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 78 |
| Start date | 15 June 2017 |
| Primary completion | 30 December 2019 |
| Estimated completion | 30 April 2020 |
| Sites | 5 locations across Denmark |
Drugs / interventions tested
- Paper diary sheet
- Monsenso DBT-app and IT monitoring program
Conditions studied
- Borderline Personality Disorder — all drugs for Borderline Personality Disorder →
- Emotional Instability — all drugs for Emotional Instability →
- Skill, Coping — all drugs for Skill, Coping →
Sponsor
Region of Southern Denmark
Who can join
18 and older, any sex, with Borderline Personality Disorder or Emotional Instability. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
BACKGROUND: Borderline Personality Disorder (BPD) is a serious and debilitating mental disease characterized by difficulties with emotion regulation that leads to unstable and self- destructive behavior and relationships. The prevalence of BPD is between 1% and 5% in the Scandinavian population with similar prevalence rates found in US epidemiologic surveys. BPD increases the risk for suicide by 4-fold, while patients with comorbid BDP and tendency to self-harm have a further 2-fold attenuated risk. BDP is difficult to treat, and even more difficult when co-occurring with other disorders. Dialectical Behavior Therapy (DBT) is the best validated treatment for BPD, showing medium to large effect sizes as compared to treatment as usual for anger, parasuicidality (suicide attempts without an intention to die) and poor mental health. DBT uses self-monitoring as the mainstay of treatment, which helps patients regulate their emotions by means of emotional regulating skills, and reduce problem behavior. Self-monitoring has traditionally been done by means of daily paper diaries. The latest developments in smartphone applications have generated alternatives for ecological momentary assessments of problematic behavior that even prompt patients to practice skills targeting emotion regulation. An example of this is Monsenso's DBT self-monitoring mHealth application (mHealth means mobile health, public health supported by mobile phones). Such applications may enhance treatment success in BPD patients, as they are available to patients at all times. OBJECTIVES: To evaluate the Monsenso's mHealth app with respect to clinical efficacy as an adjunct to DBT-psychotherapy treatment and utility as a way to measure outcomes in BPD patients. METHODS: The study will be a 2-year multi center, randomized controlled trial. In both conditions patients will be followed for one year. Self report data of DBT-skills-use, positive and negative affect, Standardised self report questionnaires on Emotion regulation ability; functioning; borderline symptoms. will be given pre, post and every month. The treatment arm (n=50) will receive the mHealth app that includes coaching suggestions and instructed how to use it. The control arm (n=50) will only use a pen and paper based self-monitoring, as traditionally used in DBT-treatment. STUDY ENDPOINTS: Primary: mean number of days passed per new DBT-Skill learned. Secondary: Borderline personality disorder(BPD)-symptoms, Emotion regulation ability, ratio positive/negative affect.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Psychological therapies for people with borderline personality disorder.
Storebø OJ, Stoffers-Winterling JM, Völlm BA, Kongerslev MT, et al · · 2020 · cited 208× · PMID 32368793 · DOI 10.1002/14651858.cd012955.pub2 -
Mobile Diary App Versus Paper-Based Diary Cards for Patients With Borderline Personality Disorder: Economic Evaluation.
Laursen SL, Helweg-Jørgensen S, Langergaard A, Søndergaard J, et al · · 2021 · cited 14× · PMID 34762057 · DOI 10.2196/28874 -
Daily Self-Monitoring of Symptoms and Skills Learning in Patients With Borderline Personality Disorder Through a Mobile Phone App: Protocol for a Pragmatic Randomized Controlled Trial.
Helweg-Jørgensen S, Beck Lichtenstein M, Fruzzetti AE, Møller Dahl C, et al · · 2020 · cited 11× · PMID 32449690 · DOI 10.2196/17737
Verify or expand the search:
- PubMed search for NCT03191565
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Borderline Personality Disorder
Currently open trials in the same condition.
- NCT06458933 — Testing Interventions for Borderline Personality Disorder. · Phase 2 · recruiting
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT07119541 — Testing an Alliance-Focused Dialectical Behaviour Therapy Training for Borderline Personality Disorder · NA · active not recruiting
- NCT06446765 — Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder · Phase 2 · recruiting
- NCT07197502 — Treatment of Borderline Personality Disorder With rTMS · NA · recruiting
Other Region of Southern Denmark trials
Trials by the same sponsor.
- NCT06655623 — A Multiple Case Study of Schema Therapy for Difficult-to-treat Depression- DEPRE-ST*Case · NA · completed
- NCT05833087 — Schema Therapy for Patients With Chronic Treatment Resistant Depression · NA · recruiting
- NCT05302518 — Virtual Reality for AnxIety Disorders - Randomized Controlled Trial · NA · completed
- NCT04610749 — Diabetic Retinopathy as a Marker of Cognitive Dysfunction and Depression · completed
- NCT04398797 — Prevention of AcuTe admIssioN Algorithm (PATINA) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03191565 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region of Southern Denmark
- Last refreshed: 25 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03191565.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing